{"pmid":32404480,"title":"Evaluation of a rapid diagnostic assay for detection of SARS CoV-2 antigen in nasopharyngeal swab.","text":["Evaluation of a rapid diagnostic assay for detection of SARS CoV-2 antigen in nasopharyngeal swab.","Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus causing causing Coronavirus disease 2019 (COVID-19) was reported for the first time in Wuhan (Hubei, China) in December 2019 (1, 2) and has become a major public health concern all over the world.....","J Clin Microbiol","Lambert-Niclot, Sidonie","Cuffel, Alexis","Le Pape, Samuel","Vauloup-Fellous, Christelle","Morand-Joubert, Laurence","Roque-Afonso, Anne-Marie","Le Goff, Jerome","Delaugerre, Constance","32404480"],"abstract":["Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus causing causing Coronavirus disease 2019 (COVID-19) was reported for the first time in Wuhan (Hubei, China) in December 2019 (1, 2) and has become a major public health concern all over the world....."],"journal":"J Clin Microbiol","authors":["Lambert-Niclot, Sidonie","Cuffel, Alexis","Le Pape, Samuel","Vauloup-Fellous, Christelle","Morand-Joubert, Laurence","Roque-Afonso, Anne-Marie","Le Goff, Jerome","Delaugerre, Constance"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404480","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1128/JCM.00977-20","locations":["Wuhan","Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666802845316284418,"score":9.490897,"similar":[{"pmid":32341143,"title":"Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens.","text":["Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (Modified CDC), the Simplexa COVID-19 Direct (Diasorin Molecular), GenMark ePlex SARS-CoV-2 assay (GenMark) and the Hologic Panther Fusion(R) SARS-CoV-2 assay (Hologic). This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made.","J Clin Microbiol","Zhen, Wei","Manji, Ryhana","Smith, Elizabeth","Berry, Gregory J","32341143"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (Modified CDC), the Simplexa COVID-19 Direct (Diasorin Molecular), GenMark ePlex SARS-CoV-2 assay (GenMark) and the Hologic Panther Fusion(R) SARS-CoV-2 assay (Hologic). This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made."],"journal":"J Clin Microbiol","authors":["Zhen, Wei","Manji, Ryhana","Smith, Elizabeth","Berry, Gregory J"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341143","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1128/JCM.00743-20","locations":["Wuhan","Hubei","China","New York"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495765184515,"score":131.95306},{"pmid":32503847,"title":"Multi-Center Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Assay for the Detection of SARS-CoV-2 in Oropharyngeal Swab Specimens.","text":["Multi-Center Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Assay for the Detection of SARS-CoV-2 in Oropharyngeal Swab Specimens.","The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a global health concern that has spread worldwide since December 2019 (1-4).....","J Clin Microbiol","Hou, Hongyan","Chen, Jun","Wang, Yueqin","Lu, Yanjun","Zhu, Yaowu","Zhang, Bo","Wang, Feng","Mao, Lie","Tang, Yi-Wei","Hu, Bicheng","Ren, Yi","Sun, Ziyong","32503847"],"abstract":["The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a global health concern that has spread worldwide since December 2019 (1-4)....."],"journal":"J Clin Microbiol","authors":["Hou, Hongyan","Chen, Jun","Wang, Yueqin","Lu, Yanjun","Zhu, Yaowu","Zhang, Bo","Wang, Feng","Mao, Lie","Tang, Yi-Wei","Hu, Bicheng","Ren, Yi","Sun, Ziyong"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503847","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1128/JCM.01288-20","topics":["Diagnosis"],"weight":1,"_version_":1668892488236007424,"score":121.987946},{"pmid":32293168,"pmcid":"PMC7172500","title":"Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.","text":["Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.","Coronavirus disease 2019 (COVID-19) is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019-nCoV). Based on the rapid increase in the rate of human infection, the World Health Organization (WHO) has classified the COVID-19 outbreak as a pandemic. Because no specific drugs or vaccines for COVID-19 are yet available, early diagnosis and management are crucial for containing the outbreak. Here, we report a field-effect transistor (FET)-based biosensing device for detecting SARS-CoV-2 in clinical samples. The sensor was produced by coating graphene sheets of the FET with a specific antibody against SARS-CoV-2 spike protein. The performance of the sensor was determined using antigen protein, cultured virus, and nasopharyngeal swab specimens from COVID-19 patients. Our FET device could detect the SARS-CoV-2 spike protein at concentrations of 1 fg/mL in phosphate-buffered saline and 100 fg/mL clinical transport medium. In addition, the FET sensor successfully detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6 x 10(1) pfu/mL) and clinical samples (LOD: 2.42 x 10(2) copies/mL). Thus, we have successfully fabricated a promising FET biosensor for SARS-CoV-2; our device is a highly sensitive immunological diagnostic method for COVID-19 that requires no sample pretreatment or labeling.","ACS Nano","Seo, Giwan","Lee, Geonhee","Kim, Mi Jeong","Baek, Seung-Hwa","Choi, Minsuk","Ku, Keun Bon","Lee, Chang-Seop","Jun, Sangmi","Park, Daeui","Kim, Hong Gi","Kim, Seong-Jun","Lee, Jeong-O","Kim, Bum Tae","Park, Edmond Changkyun","Kim, Seung Il","32293168"],"abstract":["Coronavirus disease 2019 (COVID-19) is a newly emerging human infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019-nCoV). Based on the rapid increase in the rate of human infection, the World Health Organization (WHO) has classified the COVID-19 outbreak as a pandemic. Because no specific drugs or vaccines for COVID-19 are yet available, early diagnosis and management are crucial for containing the outbreak. Here, we report a field-effect transistor (FET)-based biosensing device for detecting SARS-CoV-2 in clinical samples. The sensor was produced by coating graphene sheets of the FET with a specific antibody against SARS-CoV-2 spike protein. The performance of the sensor was determined using antigen protein, cultured virus, and nasopharyngeal swab specimens from COVID-19 patients. Our FET device could detect the SARS-CoV-2 spike protein at concentrations of 1 fg/mL in phosphate-buffered saline and 100 fg/mL clinical transport medium. In addition, the FET sensor successfully detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6 x 10(1) pfu/mL) and clinical samples (LOD: 2.42 x 10(2) copies/mL). Thus, we have successfully fabricated a promising FET biosensor for SARS-CoV-2; our device is a highly sensitive immunological diagnostic method for COVID-19 that requires no sample pretreatment or labeling."],"journal":"ACS Nano","authors":["Seo, Giwan","Lee, Geonhee","Kim, Mi Jeong","Baek, Seung-Hwa","Choi, Minsuk","Ku, Keun Bon","Lee, Chang-Seop","Jun, Sangmi","Park, Daeui","Kim, Hong Gi","Kim, Seong-Jun","Lee, Jeong-O","Kim, Bum Tae","Park, Edmond Changkyun","Kim, Seung Il"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293168","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1021/acsnano.0c02823","keywords":["2019-ncov","covid-19","fet","sars-cov-2","biosensor"],"e_drugs":["Lead","Graphite"],"topics":["Diagnosis"],"weight":1,"_version_":1666138494340169729,"score":99.1208},{"pmid":32265517,"title":"SARS-CoV-2 detection in patients with influenza-like illness.","text":["SARS-CoV-2 detection in patients with influenza-like illness.","Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, Hubei Province, China in late December 2019. We re-analysed 640 throat swabs collected from patients in Wuhan with influenza-like-illness from 6 October 2019 to 21 January 2020 and found that 9 of the 640 throat swabs were positive for SARS-CoV-2 RNA by quantitative PCR, suggesting community transmission of SARS-CoV2 in Wuhan in early January 2020.","Nat Microbiol","Kong, Wen-Hua","Li, Yao","Peng, Ming-Wei","Kong, De-Guang","Yang, Xiao-Bing","Wang, Leyi","Liu, Man-Qing","32265517"],"abstract":["Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, Hubei Province, China in late December 2019. We re-analysed 640 throat swabs collected from patients in Wuhan with influenza-like-illness from 6 October 2019 to 21 January 2020 and found that 9 of the 640 throat swabs were positive for SARS-CoV-2 RNA by quantitative PCR, suggesting community transmission of SARS-CoV2 in Wuhan in early January 2020."],"journal":"Nat Microbiol","authors":["Kong, Wen-Hua","Li, Yao","Peng, Ming-Wei","Kong, De-Guang","Yang, Xiao-Bing","Wang, Leyi","Liu, Man-Qing"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32265517","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41564-020-0713-1","locations":["Wuhan","Hubei","China","Wuhan","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Transmission"],"weight":1,"_version_":1666138491882307585,"score":97.7836},{"pmid":32462195,"title":"Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2.","text":["Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2.","OBJECTIVES: To evaluate the clinical performance of 3 molecular assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We used 184 nasopharyngeal swab specimens to compare Abbott ID NOW COVID-19 (Abbott ID NOW), DiaSorin Molecular Simplexa COVID-19 Direct (DiaSorin Simplexa), and Roche cobas 6800 SARS-CoV-2 (Roche cobas) assays. In a separate analysis, 3 specimens (nasopharyngeal, oropharyngeal, and nasal) were collected from 182 unique patients presenting to the emergency department with suspicion of coronavirus disease 2019 and were tested utilizing Abbott ID NOW. To further characterize each assay, relative limits of detection were evaluated utilizing positive nasopharyngeal patient samples. RESULTS: The positive percent agreement was 91% (95% confidence interval [CI], 0.76-0.97) for Abbott ID NOW and 100% (95% CI, 0.90-1.00) for DiaSorin Simplexa and Roche cobas. The negative percent agreement was 100% (95% CI, 0.98-1.00) for all 3 assays. All swab types tested with the Abbott assay produced concordant results. Polymerase chain reaction assays had approximately 10 to 100 times lower limits of detection than Abbott ID NOW. CONCLUSIONS: Based on these evaluations, a multiplatform testing approach is proposed, depending on patient population and assay sensitivity, to address testing needs during a public health emergency.","Am J Clin Pathol","Cradic, Kendall","Lockhart, Marie","Ozbolt, Patrick","Fatica, Lisa","Landon, Lorie","Lieber, Michael","Yang, David","Swickard, Juanita","Wongchaowart, Nicholas","Fuhrman, Susan","Antonara, Stella","32462195"],"abstract":["OBJECTIVES: To evaluate the clinical performance of 3 molecular assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We used 184 nasopharyngeal swab specimens to compare Abbott ID NOW COVID-19 (Abbott ID NOW), DiaSorin Molecular Simplexa COVID-19 Direct (DiaSorin Simplexa), and Roche cobas 6800 SARS-CoV-2 (Roche cobas) assays. In a separate analysis, 3 specimens (nasopharyngeal, oropharyngeal, and nasal) were collected from 182 unique patients presenting to the emergency department with suspicion of coronavirus disease 2019 and were tested utilizing Abbott ID NOW. To further characterize each assay, relative limits of detection were evaluated utilizing positive nasopharyngeal patient samples. RESULTS: The positive percent agreement was 91% (95% confidence interval [CI], 0.76-0.97) for Abbott ID NOW and 100% (95% CI, 0.90-1.00) for DiaSorin Simplexa and Roche cobas. The negative percent agreement was 100% (95% CI, 0.98-1.00) for all 3 assays. All swab types tested with the Abbott assay produced concordant results. Polymerase chain reaction assays had approximately 10 to 100 times lower limits of detection than Abbott ID NOW. CONCLUSIONS: Based on these evaluations, a multiplatform testing approach is proposed, depending on patient population and assay sensitivity, to address testing needs during a public health emergency."],"journal":"Am J Clin Pathol","authors":["Cradic, Kendall","Lockhart, Marie","Ozbolt, Patrick","Fatica, Lisa","Landon, Lorie","Lieber, Michael","Yang, David","Swickard, Juanita","Wongchaowart, Nicholas","Fuhrman, Susan","Antonara, Stella"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462195","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/ajcp/aqaa097","keywords":["abbott id now","covid-19","coronavirus","molecular diagnostics","sars-cov-2"],"locations":["Abbott"],"topics":["Diagnosis"],"weight":1,"_version_":1668079521248575489,"score":96.45826}]}